In this context, it is essential to emphasize that in numerous studies concentrated specifically on CIS and RRMS, the levels of investigated biomarkers (NfL, CXCL-13 or YKL-40) did not correlate with physical disability status or disease progression [19,82,83]. The gene discussed is NEFL; the disease is in situ carcinoma.